80 related articles for article (PubMed ID: 9930297)
1. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model.
Souberbielle BE; Westby M; Ganz S; Kayaga J; Mendes R; Morrow WJ; Dalgleish AG
Gene Ther; 1998 Nov; 5(11):1447-54. PubMed ID: 9930297
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
3. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
4. A study on anti-tumor immunity induced by gene-modified melanoma B16 cells.
Fang L; Wang K; Liu X; Zhang L; Zhang X; Qian L; Lu J; Qian G; Ge S
Oncol Rep; 2008 Jun; 19(6):1589-95. PubMed ID: 18497970
[TBL] [Abstract][Full Text] [Related]
5. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
7. [Anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Wei Y; Kan B
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):118-21. PubMed ID: 11783014
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.
Kuriyama H; Shimizu K; Lee W; Kjaergaard J; Parkhurst MR; Cohen PA; Shu S
Dev Biol (Basel); 2004; 116():169-78; discussion 179-86. PubMed ID: 15603192
[TBL] [Abstract][Full Text] [Related]
9. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
10. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.
Mac Keon S; Gazzaniga S; Mallerman J; Bravo AI; Mordoh J; Wainstok R
Vaccine; 2010 Nov; 28(51):8162-8. PubMed ID: 20937314
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
[TBL] [Abstract][Full Text] [Related]
14. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
15. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
16. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
[TBL] [Abstract][Full Text] [Related]
17. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF
Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254
[TBL] [Abstract][Full Text] [Related]
18. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine.
Souberbielle BE; Knight BC; Morrow WJ; Darling D; Fraziano M; Marriott JB; Cookson S; Farzaneh F; Dalgleish AG
Gene Ther; 1996 Oct; 3(10):853-8. PubMed ID: 8908498
[TBL] [Abstract][Full Text] [Related]
19. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
[TBL] [Abstract][Full Text] [Related]
20. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis.
Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC
Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
